Yi Zhang and shareholders representing over 59.2% of the outstanding shares of YS Biopharma Co., Ltd. (company or YS) announced the successful approval of all resolutions at the YS Extraordinary General Meeting of Shareholders (EGM) held on February 16, 2024. Immediately following the successful conclusion of the EGM, the new board of directors of the Company voted [unanimously] to effect the following resolutions (among others): the removal of Chunyuan (Brenda) Wu from all positions with the Company and any subsidiaries of the Company, including without limitation as chief financial officer of the Company; the appointment Hongman Jia as the chief financial officer of the Company.